Aspire Biopharma (ASBP) Competitors $0.53 +0.00 (+0.28%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ASBP vs. ANEB, MGNX, SAVA, TCRX, ANRO, SPRO, HLVX, CNTB, SKYE, and ONCYShould you be buying Aspire Biopharma stock or one of its competitors? The main competitors of Aspire Biopharma include Anebulo Pharmaceuticals (ANEB), MacroGenics (MGNX), Cassava Sciences (SAVA), TScan Therapeutics (TCRX), Alto Neuroscience (ANRO), Spero Therapeutics (SPRO), HilleVax (HLVX), Connect Biopharma (CNTB), Skye Bioscience (SKYE), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. Aspire Biopharma vs. Its Competitors Anebulo Pharmaceuticals MacroGenics Cassava Sciences TScan Therapeutics Alto Neuroscience Spero Therapeutics HilleVax Connect Biopharma Skye Bioscience Oncolytics Biotech Anebulo Pharmaceuticals (NASDAQ:ANEB) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has higher valuation and earnings, ANEB or ASBP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-10.04Aspire BiopharmaN/AN/A-$12.54MN/AN/A Do analysts recommend ANEB or ASBP? Anebulo Pharmaceuticals presently has a consensus target price of $5.50, suggesting a potential upside of 110.73%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Anebulo Pharmaceuticals is more favorable than Aspire Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Aspire Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor ANEB or ASBP? In the previous week, Aspire Biopharma had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 1.87 beat Aspire Biopharma's score of 1.47 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Anebulo Pharmaceuticals Very Positive Aspire Biopharma Positive Which has more risk & volatility, ANEB or ASBP? Anebulo Pharmaceuticals has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500. Comparatively, Aspire Biopharma has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ANEB or ASBP? 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 48.0% of Aspire Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ANEB or ASBP more profitable? Aspire Biopharma's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -90.11% -84.53% Aspire Biopharma N/A N/A -737.96% SummaryAnebulo Pharmaceuticals beats Aspire Biopharma on 8 of the 11 factors compared between the two stocks. Get Aspire Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASBP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASBP vs. The Competition Export to ExcelMetricAspire BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.39M$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E RatioN/A21.2231.5526.39Price / SalesN/A206.92382.8986.63Price / CashN/A44.2437.7259.11Price / Book-2.808.0710.106.62Net Income-$12.54M-$54.08M$3.26B$265.42M7 Day Performance2.50%3.95%3.58%3.45%1 Month Performance6.62%3.03%3.69%0.45%1 Year PerformanceN/A6.84%37.69%19.41% Aspire Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASBPAspire BiopharmaN/A$0.53+0.3%N/AN/A$26.39MN/A0.00N/APositive NewsANEBAnebulo Pharmaceuticals2.3323 of 5 stars$2.60+5.7%$5.50+111.5%+42.8%$106.82MN/A0.004Positive NewsMGNXMacroGenics4.3743 of 5 stars$1.69+17.4%$3.60+113.0%-49.2%$106.82M$149.96M0.00430Positive NewsHigh Trading VolumeSAVACassava Sciences1.9553 of 5 stars$2.20+2.3%$2.00-9.1%-92.4%$106.28MN/A0.0030TCRXTScan Therapeutics3.0988 of 5 stars$1.87+7.5%$7.80+317.1%-66.7%$105.83M$2.82M0.00100ANROAlto Neuroscience1.8832 of 5 stars$3.91+8.8%$8.50+117.6%-64.4%$105.60MN/A0.00N/ASPROSpero Therapeutics4.0688 of 5 stars$1.87+0.5%$5.00+167.4%+36.5%$105.23M$47.98M0.00150Positive NewsHLVXHilleVax1.4392 of 5 stars$2.06-0.5%$2.00-2.9%+6.6%$103.29MN/A0.0020CNTBConnect Biopharma3.4166 of 5 stars$1.83+5.8%$7.00+282.5%+69.6%$101.97M$26.03M0.00110Positive NewsGap UpSKYESkye Bioscience1.6194 of 5 stars$3.29-7.3%$15.50+371.1%-47.8%$101.95MN/A0.0011ONCYOncolytics Biotech2.0158 of 5 stars$1.01flat$5.00+395.0%+6.3%$101.36MN/A0.0030 Related Companies and Tools Related Companies ANEB Alternatives MGNX Alternatives SAVA Alternatives TCRX Alternatives ANRO Alternatives SPRO Alternatives HLVX Alternatives CNTB Alternatives SKYE Alternatives ONCY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASBP) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aspire Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aspire Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access